Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease

Kidney International

Volumn 72, Issue 3, 2007, Pages 290-299

  Wang, Y ^a   Wang, Y P ^a   Zheng, G ^a   Lee, V W S ^a   Ouyang, L ^a   Chang, D H H ^a   Mahajan, D ^a   Coombs, J ^a   Wang, Y M ^b   Alexander, S I ^b   Harris, D C H ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Cell transfer; Chronic renal disease; Macrophages

Indexed keywords

CHEMOKINE; DOXORUBICIN; INTERLEUKIN 13; INTERLEUKIN 4; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CELL ISOLATION; CELLULAR DISTRIBUTION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DOWN REGULATION; FOCAL GLOMERULOSCLEROSIS; HISTOLOGY; IMMUNE DEFICIENCY; IMMUNE INJURY; INFLAMMATORY DISEASE; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINES, CC; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DOXORUBICIN; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; INTERLEUKIN-10; INTERLEUKIN-13; INTERLEUKIN-4; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; NITRIC OXIDE SYNTHASE TYPE II; PHENOTYPE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547461118     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002275     Document Type: Article

References (47)

1. Eddy AA. Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 1994; 5: 1273-1287.
2. Atkins RC. Macrophages in renal injury. Am J Kidney Dis 1998; 31: xlv-xlvii.
3. Main IW, Nikolic-Paterson DJ, Atkins RC. T cells and macrophages and their role in renal injury. Semin Nephrol 1992; 12: 395-407.
4. Lee VW, Wang Y, Qin X et al. Adriamycin nephropathy in severe combined immunodeficient (SCID) mice. Nephrol Dial Transplant 2006; 21: 3293-3298.
5. Wang Y, Mahajan D, Tay YC et al. Partial depletion of macrophages by ED7 reduces renal injury in Adriamycin nephropathy. Nephrology (Carlton) 2005; 10: 470-477.
6. Duffield JS, Tipping PG, Kipari T et al. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol 2005; 167: 1207-1219.
7. Zheng G, Zheng L, Wang Y et al. NK cells do not mediate renal injury in murine adriamycin nephropathy. Kidney Int 2006; 69: 1159-1165.
8. Erwig LP, Kluth DC, Rees AJ. Macrophage heterogeneity in renal inflammation. Nephrol Dial Transplant 2003; 18: 1962-1965.
9. Friedman SL. Mac the knife? Macrophages - the double-edged sword of hepatic fibrosis. J Clin Invest 2005; 115: 29-32.
10. Sutterwala FS, Noel GJ, Salgame P et al. Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I. J Exp Med 1998; 188: 217-222.
11. Herbert DR, Holscher C, Mohrs M et al. Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 2004; 20: 623-635.
12. Nishida M, Fujinaka H, Matsusaka T et al. Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest 2002; 110: 1859-1868.
13. Kluth DC, Ainslie CV, Pearce WP et al. Macrophages transfected with adenovirus to express IL-4 reduce inflammation in experimental glomerulonephritis. J Immunol 2001; 166: 4728-4736.
14. Ma J, Chen T, Mandelin J et al. Regulation of macrophage activation. Cell Mol Life Sci 2003; 60: 2334-2346.
15. Katakura T, Miyazaki M, Kobayashi M et al. CCL17 and IL-10 as effectors that enable alternatively activated macrophages to inhibit the generation of classically activated macrophages. J Immunol 2004; 172: 1407-1413.
16. Zhang J, Tachado SD, Patel N et al. Negative regulatory role of mannose receptors on human alveolar macrophage proinflammatory cytokine release in vitro. J Leukoc Biol 2005; 78: 665-674.
17. Stumpo R, Kauer M, Martin S et al. Alternative activation of macrophage by IL-10. Pathobiology 1999; 67: 245-248.
18. Kodelja V, Muller C, Politz O et al. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol 1998; 160: 1411-1418.
19. Goerdt S, Orfanos CE. Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 1999; 10: 137-142.
20. Stein M, Keshav S, Harris N et al. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992; 176: 287-292.
21. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
22. Gratchev A, Guillot P, Hakiy N et al. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Scand J Immunol 2001; 53: 386-392.
23. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003; 73: 209-212.
24. Ikezumi Y, Atkins RC, Nikolic-Paterson DJ. Interferon-gamma augments acute macrophage-mediated renal injury via a glucocorticoid-sensitive mechanism. J Am Soc Nephrol 2003; 14: 888-898.
25. Ikezumi Y, Hurst LA, Masaki T et al. Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation. Kidney Int 2003; 63: 83-95.
26. Goerdt S, Politz O, Schledzewski K et al. Alternative versus classical activation of macrophages. Pathobiology 1999; 67: 222-226.
27. Song E, Ouyang N, Horbelt M et al. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol 2000; 204: 19-28.
28. Erwig LP, Kluth DC, Walsh GM et al. Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. J Immunol 1998; 161: 1983-1988.
29. Hesse M, Modolell M, La Flamme AC et al. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol 2001; 167: 6533-6544.
30. Stout RD, Jiang C, Matta B et al. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005; 175: 342-349.
31. Wilson HM, Kluth DC. Targeting genetically modified macrophages to the glomerulus. Nephron Exp Nephrol 2003; 94: e113-e118.
32. Yang J, Reutzel-Selke A, Steier C et al. Targeting of macrophage activity by adenovirus-mediated intragraft overexpression of TNFRp55-Ig, IL-12p40, and vIL-10 ameliorates adenovirus-mediated chronic graft injury, whereas stimulation of macrophages by overexpression of IFN-gamma accelerates chronic graft injury in a rat renal allograft model. J Am Soc Nephrol 2003; 14: 214-225.
33. El-Shemi AG, Fujinaka H, Matsuki A et al. Suppression of experimental crescentic glomerulonephritis by interleukin-10 gene transfer. Kidney Int 2004; 65: 1280-1289.
34. Vielhauer V, Berning E, Eis V et al. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int 2004; 66: 2264-2278.
35. Trepicchio WL, Wang L, Bozza M et al. IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappaB. J Immunol 1997; 159: 5661-5670.
36. Yokoo T, Ohashi T, Utsunomiya Y et al. Prophylaxis of antibody-induced acute glomerulonephritis with genetically modified bone marrow-derived vehicle cells. Hum Gene Ther 1999; 10: 2673-2678.
37. Wilson HM, Stewart KN, Brown PA et al. Bone-marrow-derived macrophages genetically modified to produce IL-10 reduce injury in experimental glomerulonephritis. Mol Ther 2002; 6: 710-717.
38. Yamagishi H, Yokoo T, Imasawa T et al. Genetically modified bone marrow-derived vehicle cells site specifically deliver an anti-inflammatory cytokine to inflamed interstitium of obstructive nephropathy. J Immunol 2001; 166: 609-616.
39. Wilson HM, Chettibi S, Jobin C et al. Inhibition of macrophage nuclear factor-kappaB leads to a dominant anti-inflammatory phenotype that attenuates glomerular inflammation in vivo. Am J Pathol 2005; 167: 27-37.
40. Wells CA, Ravasi T, Faulkner GJ et al. Genetic control of the innate immune response. BMC Immunol 2003; 4: 5.
41. Polak J, Hench L. Gene therapy progress and prospects: in tissue engineering. Gene Ther 2005; 24: 1725-1733.
42. Minto AW, Erwig LP, Rees AJ. Heterogeneity of macrophage activation in anti-Thy-1.1 nephritis. Am J Pathol 2003; 163: 2033-2041.
43. Duffield JS, Erwig LP, Wei X et al. Activated macrophages direct apoptosis and suppress mitosis of mesangial cells. J Immunol 2000; 164: 2110-2119.
44. Wang Y, Wang YP, Tay YC et al. Progressive adriamycin nephropathy in mice :sequence of histologic and immunohistochemical events. Kidney Int 2000; 58: 1797-1804.
45. Blumenthal R, Sarkar DP, Durell S et al. Dilation of the influenza hemagglutinin fusion pore revealed by the kinetics of individual cell-cell fusion events. J Cell Biol 1996; 135: 63-71.
46. Mizuno S, Kurosawa T, Matsumoto K et al. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J Clin Invest 1998; 101: 1827-1834.
47. Saito T, Sumithran E, Glasgow EF et al. The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int 1987; 32: 691-699.